M
Max M. L. Knott
Researcher at Ludwig Maximilian University of Munich
Publications - 6
Citations - 274
Max M. L. Knott is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Chemokine & CCL22. The author has an hindex of 4, co-authored 6 publications receiving 139 citations.
Papers
More filters
Journal ArticleDOI
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes
Moritz Rapp,Maximilian W.M. Wintergerst,Wolfgang G. Kunz,Viola Vetter,Max M. L. Knott,Dominik Lisowski,Sascha Haubner,Stefan Moder,Raffael Thaler,Stephan Eiber,Bastian Meyer,Natascha Röhrle,Ignazio Piseddu,Simon Grassmann,Patrick Layritz,Benjamin Kühnemuth,Susanne Stutte,Carole Bourquin,Carole Bourquin,Ulrich H. von Andrian,Ulrich H. von Andrian,Stefan Endres,David Anz +22 more
TL;DR: It is demonstrated that CCL22 expression by dendritic cells (DCs) promotes the formation of cell–cell contacts and interaction with regulatory T cells (T reg) through their CCR4 receptor, identified as an immune checkpoint that is crucial for the control of T cell immunity.
Journal ArticleDOI
Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells
Gabriela M. Wiedemann,Max M. L. Knott,Viola Vetter,Moritz Rapp,Sascha Haubner,Julia Fesseler,Benjamin Kühnemuth,Patrick Layritz,Raffael Thaler,Stephan Kruger,Steffen Ormanns,Doris Mayr,Stefan Endres,David Anz +13 more
TL;DR: It is demonstrated here that intratumoral CCL22 is induced in tumor-infiltrating immune cells through cancer cell-derived interleukin-1 (IL-1α), which could represent a promising strategy to inhibit tumor-induced immunosuppression.
Journal ArticleDOI
Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.
David Anz,Moritz Rapp,Stephan Eiber,Viktor H. Koelzer,Raffael Thaler,Sascha Haubner,Max M. L. Knott,Sarah Nagel,Michaela Golic,Gabriela M. Wiedemann,Franz Bauernfeind,Cornelia Wurzenberger,Veit Hornung,Christoph Scholz,Doris Mayr,Simon Rothenfusser,Stefan Endres,Carole Bourquin,Carole Bourquin +18 more
TL;DR: It is argued that type I IFN blocks the Treg-attracting chemokine CCL22 and thus helps limit the recruitment of Treg to tumors, a finding with implications for cancer immunotherapy.
Book ChapterDOI
CCL22 Signaling in the Tumor Environment
TL;DR: T cell-mediated elimination of malignant cells is one cornerstone of endogenous and therapeutically induced antitumor immunity and therapeutic interventions to the CCL22-CCR4 axis may represent a promising strategy in cancer immunotherapy.